Why Are UniQure Shares Surging Today?
Why Are UniQure Shares Surging Today?
UniQure N.V. (NASDAQ:QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.
UniQure N.V.（納斯達克：QURE）股票正在飆升，這是因爲其AMt-130的I/II期臨床試驗發佈了有希望的中期數據，該基因療法旨在治療亨廷頓病。
What's Going On: The latest results, which include up to 24 months of follow-up data from 29 patients across the U.S. and Europe, demonstrated a significant slowing of disease progression. Patients treated with AMT-130 exhibited an impressive 80% reduction in disease progression compared to a control group, as measured by the Unified Huntington's Disease Rating Scale (cUHDRS).
最新的結果顯示，來自美國和歐洲的29名患者的長達24個月的隨訪數據顯示，疾病進展顯著減緩。與對照組相比，接受AMt-130治療的患者，根據統一亨廷頓病評分量表(cUHDRS)所測量的疾病進展率減少了令人印象深刻的80%。
Additionally, levels of neurofilament light protein (NfL) in cerebrospinal fluid, a key biomarker of neurodegeneration, decreased markedly in patients receiving the therapy.
此外，接受該療法治療的患者的腦脊液中神經絲輕鏈蛋白（NfL）水平顯著下降，這是神經退行性疾病的關鍵生物標誌物。
What Else: The company's achievement of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation further underscores the therapy's potential to address unmet medical needs expediently and prepares for discussions with the FDA in late 2024 to explore accelerated approval pathways.
公司獲得的FDA再生醫學先進療法（RMAT）認證進一步突顯了該療法解決未滿足的醫療需求的潛力，併爲2024年底與FDA探討加速批准途徑做好了準備。
QURE Price Action: UniQure shares were up by 61.2% at $10.78 according to Benzinga Pro.
UniQure股價上漲61.2%，至10.78美元，據Benzinga Pro報道。
Image: Shutterstock/ solarseven.
圖片：shutterstock / solarseven。